Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E22.50 EPS (ttm)2.32 Insider Own0.10% Shs Outstand1.64B Perf Week0.42%
Market Cap85.44B Forward P/E14.13 EPS next Y3.70 Insider Trans-8.56% Shs Float1.63B Perf Month2.09%
Income3.82B PEG2.05 EPS next Q0.86 Inst Own73.20% Short Float0.78% Perf Quarter-22.44%
Sales21.04B P/S4.06 EPS this Y-10.90% Inst Trans1.12% Short Ratio1.48 Perf Half Y-15.56%
Book/sh7.83 P/B6.67 EPS next Y8.45% ROA2.70% Target Price59.20 Perf Year-3.30%
Cash/sh4.14 P/C12.62 EPS next 5Y10.99% ROE6.80% 52W Range49.96 - 70.05 Perf YTD-14.75%
Dividend1.60 P/FCF42.48 EPS past 5Y15.30% ROI20.20% 52W High-25.42% Beta0.94
Dividend %3.06% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin70.40% 52W Low4.56% ATR1.14
Employees23700 Current Ratio1.50 Sales Q/Q5.40% Oper. Margin23.70% RSI (14)39.35 Volatility1.59% 1.96%
OptionableYes Debt/Eq0.60 EPS Q/Q-3.80% Profit Margin4.40% Rel Volume0.63 Prev Close52.24
ShortableYes LT Debt/Eq0.45 EarningsApr 26 BMO Payout280.50% Avg Volume8.61M Price52.24
Recom2.50 SMA200.76% SMA50-8.97% SMA200-14.55% Volume0 Change0.00%
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
May-21-18 07:15AM  Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space ACCESSWIRE
May-16-18 05:07PM  Bristol-Myers Squibb Highlights Breadth of Immuno-OncologyBased Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018 Business Wire
07:09AM  Jim Cramer Advises His Viewers On Consolidated Edison, L Brands And More Benzinga
May-15-18 06:59PM  Cramer's lightning round: Take a pass on Bristol-Myers Sq... CNBC Videos
06:47PM  Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now CNBC
02:28PM  Nektar Therapeutics Stock Is Risky But Offers Big Reward InvestorPlace
06:59AM  Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference Business Wire
May-10-18 05:50PM  Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs American City Business Journals
02:58PM  MARKETS: Biotech and pharma stocks could be the key to the market bull case Yahoo Finance Video
May-09-18 11:20AM  Why Bristol-Myers Squibb Stock Crashed in April Motley Fool
May-07-18 02:32AM  Roche's Tecentriq combo wins fast FDA review in race to catch rivals Reuters
May-04-18 05:35PM  As emergency blood-thinner antidote scores FDA OK, Peninsula drug maker's stock soars American City Business Journals
02:14PM  Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote Benzinga
11:55AM  Q1 Earnings Drag Pharma ETFs Down Zacks
08:00AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
May-03-18 10:24AM  What's in Store for Celldex (CLDX) This Earnings Season? Zacks
08:38AM  European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire
May-02-18 09:31AM  The Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and Honda Zacks
08:30AM  Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement Business Wire
07:30AM  Flatiron Health, Purchased By Roche, Signs Three-Year Deal With Bristol-Myers Forbes
May-01-18 04:39PM  How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer American City Business Journals
04:11PM  Dow Jones' Merck Slides On Mixed First Quarter As Keytruda Sales Pop Investor's Business Daily
03:41PM  Stephanie Link adds to Zimmer Biomet after earnings & bets on one gambling giant CNBC
11:05AM  Top Stock Reports for Amazon, Bristol-Myers & Time Warner Zacks
07:21AM  Sales of cancer drug Keytruda power Merck to a first-quarter earnings beat CNBC
Apr-30-18 04:47PM  Can These Top-Performing Biotech Stocks Keep Climbing? Motley Fool
Apr-27-18 03:12PM  BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position Benzinga
08:17AM  Is Bristol-Myers Squibb Stock a Buy After Its Mixed Q1 Results? Motley Fool
07:00AM  Advantagene Announces Clinical Trial Collaboration GlobeNewswire
Apr-26-18 10:16PM  Edited Transcript of BMY earnings conference call or presentation 26-Apr-18 2:30pm GMT Thomson Reuters StreetEvents
04:29PM  How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily
12:15PM  Bristol-Myers Squibb Co Reports Earnings for First Quarter of 2018 InvestorPlace
12:03PM  Bristol-Myers raises 2018 forecast, some sales disappoint Reuters
11:15AM  Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire
10:21AM  Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses Zacks
10:05AM  Drug Makers: A Dose of Robust Earnings
09:28AM  Stocks to Watch: Facebook, Qualcomm, AT&T, Ford, GM, Chipotle, Visa, eBay, Amazon, PayPal, Southwest The Wall Street Journal
09:20AM  Bristol-Myers Squibb Company to Host Earnings Call ACCESSWIRE
08:28AM  How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily
07:29AM  Bristol-Myers (BMY) Q1 Earnings Beat Estimates Zacks
07:22AM  Bristol-Myers reports Q1 profit beat, revenue miss MarketWatch
07:18AM  Bristol-Myers: 1Q Earnings Snapshot Associated Press
07:15AM  Bristol-Myers' cancer drug Opdivo fuels growth, but revenue falls short CNBC
Apr-25-18 04:20PM  European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma Business Wire
03:07PM  Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to Selling
10:56AM  Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX Zacks
08:52AM  Why Bristol-Myers (BMY) Might Surprise This Earnings Season Zacks
Apr-24-18 07:14PM  Cramer Remix: Navigating buying opportunities in tech amid a sell-off CNBC
07:01PM  Cramer's lightning round: Wait for Take Two's earnings before buying CNBC
01:14PM  Why Bristol-Myers Squibb Companys (NYSE:BMY) ROE Of 8.23% Does Not Tell The Whole Story Simply Wall St.
06:00AM  Amid drug price worries, earnings to test U.S. pharma, biotech shares Reuters
Apr-23-18 04:36PM  Amid drug price worries, earnings to test U.S. pharma, biotech shares Reuters
10:00AM  Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings? Zacks
Apr-20-18 08:35PM  Aptevo executive Jane Gross jumped to a startup and landed in the C-Suite American City Business Journals
10:43AM  Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR Zacks
Apr-19-18 05:44PM  Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer Zacks
10:38AM  EARNINGS: Philip Morris misses on revenue, selling fewer cigarettes in Saudi Arabia Yahoo Finance Video
Apr-18-18 04:15PM  U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review Business Wire
12:41PM  Trader adding to this beaten pharma stock CNBC Videos
10:35AM  NEWS BITES: Barbara Bush dies at 92, Sessions proposes new limits on opioid production, tax day extended Yahoo Finance Video
07:45AM  The Newest, Undiscovered CAR-T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside Potential ACCESSWIRE
Apr-17-18 02:29PM  Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It Bloomberg
02:16PM  One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings Benzinga
12:13PM  Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY) Simply Wall St.
10:52AM  Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better Zacks
10:44AM  MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade Yahoo Finance Video
08:34AM  Stocks Push Forward As Fears of War Diminish InvestorPlace
08:20AM  Todays Research Reports on Trending Tickers: Bristol-Myers Squibb and TESARO ACCESSWIRE
06:58AM  Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets MarketWatch
06:32AM  Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets Motley Fool
12:45AM  [$$] New Drug Combinations Improve Survival in Lung Cancer The Wall Street Journal
Apr-16-18 04:57PM  What Happened in the Stock Market Today Motley Fool -7.79%
04:41PM  Bristol-Myers Partners With Janssen on Anticlotting Therapy Bloomberg
04:32PM  The Biggest Movers: J.B. Hunt Jumps; Bristol Myers Drops
04:26PM  Bristol Topples After Merck Treatment Outperforms It In Lung Cancer Tests Investor's Business Daily
04:15PM  Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy Business Wire
04:03PM  In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Business Wire
02:09PM  Merck extends lead over Bristol-Myers in lung cancer race CNBC Videos
01:33PM  Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs Bloomberg Video
01:33PM  Merck Expands Lead Over Bristol-Meyers in Lung Cancer Drugs Bloomberg
01:18PM  Merck to move scientists and money toward promising cancer drug American City Business Journals
12:52PM  U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Business Wire
12:05PM  [$$] Bristol-Myers Has Farther to Fall The Wall Street Journal
11:35AM  Survival data boosts Merck's Keytruda lead in lung cancer Reuters
11:17AM  Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data
10:37AM  Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo Zacks
10:12AM  Merck shares rise after beating rivals' lung cancer results MarketWatch
09:38AM  Bristol-Myers and Merck meet cancer study goals CNBC Videos
09:30AM  [$$] New Drug Combinations Improve Survival in Lung Cancer The Wall Street Journal
09:30AM  Merck Keeps Edge Over Bristol-Myers In Cancer Duel Forbes
09:30AM  Merck drug results suggest it will extend its lead in lung cancer; Bristol-Myers shares drop CNBC
09:30AM  Merck Cements Lead in Lung Cancer With Bristol-Myers Fizzling Bloomberg
09:24AM  Bristol-Myers says cancer drug combo reduces death risk Reuters
09:19AM  Bristol-Myers Says Lung Cancer Drug Combination Met Trial Goal Bloomberg
09:05AM  Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB) Business Wire
07:10AM  Stock Market Futures Rally After Syria Mission 'Accomplished'; These 5 S&P 500 Stocks Have Big News Investor's Business Daily
Apr-15-18 09:30PM  [$$] Merck lung cancer trial boosts immunotherapy hopes Financial Times
Apr-13-18 04:51PM  Illumina shares advance on Bristol-Myers cancer drug collaboration MarketWatch
04:34PM  Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC) Business Wire
04:15PM  Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibbs Oncology Immunotherapies Business Wire
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM
Caldarella Joseph CSVP & ControllerSep 06Sale60.009,340560,40046,297Sep 08 04:31 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,594038,811Sep 06 04:46 PM
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM